Akari Cost Of Revenue from 2010 to 2024

AKTX Stock  USD 1.14  0.11  10.68%   
Akari Therapeutics Cost Of Revenue yearly trend continues to be fairly stable with very little volatility. Cost Of Revenue will likely drop to 3,800 in 2024. During the period from 2010 to 2024, Akari Therapeutics Cost Of Revenue regression line of annual values had r-squared of  0.02 and arithmetic mean of  9,072. View All Fundamentals
 
Cost Of Revenue  
First Reported
2014-12-31
Previous Quarter
1000
Current Value
13 K
Quarterly Volatility
575 K
 
Yuan Drop
 
Covid
Check Akari Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akari Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 6.4 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 18 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Akari financial statements analysis is a perfect complement when working with Akari Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Akari Therapeutics Correlation against competitors.

Latest Akari Therapeutics' Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Akari Therapeutics PLC over the last few years. Cost of Revenue is found on Akari Therapeutics PLC income statement and represents the costs associated with goods and services Akari Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Akari Therapeutics' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akari Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Pretty Stable
   Cost Of Revenue   
       Timeline  

Akari Cost Of Revenue Regression Statistics

Arithmetic Mean9,072
Geometric Mean0.00
Coefficient Of Variation154.71
Mean Deviation10,033
Median3,800
Standard Deviation14,035
Sample Variance197M
Range42.4K
R-Value0.15
Mean Square Error207.3M
R-Squared0.02
Significance0.59
Slope475.30
Total Sum of Squares2.8B

Akari Cost Of Revenue History

2024 3800.0
2023 4000.0
2022 3708.0
2021 4126.0
2020 8907.0
201919.2 K
201842.4 K

About Akari Therapeutics Financial Statements

Akari Therapeutics investors use historical fundamental indicators, such as Akari Therapeutics' Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Akari Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of RevenueK3.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.